Company intelligence / Profile preview

Scienture

Ownership: Public · SCNX
Development stage: Commercial

Overview

The company has announced FDA Orange Book patent listing and manufacturing readiness for its lead product, Arbli™ (losartan potassium oral suspension), with commercial launch targeted for July 2025. No clinical trial results are detailed in public sources.

Therapeutic areas: Cardiovascular
Modalities: Small molecule
Industry: Biotech

Drug pipeline

2 assets

SCN-106

Unknown

1 more asset in the full pipeline.

Partnerships

Syneos Health

Financials

Market cap: $5.1M
Total revenue: $431.6K
Enterprise value: $7.6M

Beyond the preview

Go deeper on Scienture.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Scienture.